Golidocitinib：首次批准。
Golidocitinib: First Approval.
发表日期：2024 Sep 19
作者：
Susan J Keam
来源：
DRUGS
摘要：
Golidocitinib (®) 是一种口服、强效、选择性 Janus 激酶 1 (JAK1) 抑制剂，由迪扎尔（江苏）制药有限公司开发，用于治疗癌症，包括外周 T 细胞淋巴瘤 (PTCL)。 2024年6月，戈利多西替尼在中国获得有条件批准，用于治疗已接受至少一种全身治疗的复发或难治性（r/r）PTCL成人患者。本文总结了戈利多西替尼 (golidocitinib) 开发的里程碑，该药物首次获批用于治疗成人 PTCL。© 2024。作者获得 Springer Nature Switzerland AG 的独家许可。
Golidocitinib (®) is an oral, potent, selective Janus kinase 1 (JAK1) inhibitor being developed by Dizal (Jiangsu) Pharmaceutical Co., Ltd for the treatment of cancer, including peripheral T cell lymphoma (PTCL). In June 2024, golidocitinib received conditional approval in China for the treatment of adult patients with relapsed or refractory (r/r) PTCL who have received at least one line of systemic treatment. This article summarizes the milestones in the development of golidocitinib leading to this first approval for the treatment of adults with PTCL.© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.